๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

โœ Scribed by E. Leitersdorf; S. Eisenberg; O. Eliav; N. Berkman; E. J. Dann; D. Landsberger; E. Sehayek; V. Meiner; T. K. Peters; E. N. Muratti; J. -M. Bard; J. -C. Fruchart; Y. Stein


Publisher
Springer
Year
1993
Tongue
English
Weight
693 KB
Volume
45
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Safety and efficacy of high-dose chemoth
โœ Benjamin Chen; Tauseef Ahmed; Anney Mannancheril; Michael Gruber; Deborah L. Ben ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 92 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Malignant astrocytomas are among the most resistant tumors to curative treatments. Mean survival without treatment is measured in weeks, and even with maximal surgery and radiation, the mean reported survival is < 1 year. The advent of supportive treatments and newer agen

Anxiolytic efficacy and safety evaluatio
โœ John Karkalas; Dr. Harbans Lal ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 211 KB

Therapeutic efficacy of high doses of oxazepam was evaluated in highly anxious psychoneurotic, psychotic depressive and schizophrenic patients. Evaluation through Hamilton Anxiety Scale, Serax-lsosorbide Dinitrate Self Rating Scale, and Brief Psychiatric Rating Scale showed significant reduction of

Safety and efficacy of high dose of venl
โœ P. Mbaya ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 57 KB ๐Ÿ‘ 1 views

## Abstract ## Aim The aim of the study was to look at efficacy and the safety profile of high dose (450โ€“600โ€‰mg) venlafaxine XL in five patients with treatment resistant major depressive illness. ## Methods Five patients with treatment resistant depression were treated with high dose venlafaxine

Efficacy and safety of bortezomib in pat
โœ Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Gugl ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 104 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor. Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of borte